Combined with current ICIs and/or targeted therapies, drugs modulating ILC plasticity toward an anti-tumor phenotype and/or targeting their effector molecules might thus represent an innovative therapeutic strategy to improve the outcome of metastatic melanoma patients. This evidence concerns the gene CCL27 and neoplasm.